P-04 ABO MAJOR INCOMPATIBILITY IN ALLOGENEIC BONE MARROW TRANSPLANTATION: RBC REMOVAL WITH COMTEC CELL SEPARATOR

Abstract

The Myelodysplastic syndrome (MDS) is characterized by peripheral blood cytopenia and dysplastic changes of one or more cell lines in the bone marrow. There is an increased risk of transformation to acute myelogenous leukemia in time. A significant proportion of the patients require blood product due to severe anemia and/or thrombocytopenia. Our objective in this retrospective study was, to determine the characteristics of patients with respect to blood product requirement and to determine whether there was a change in transfusion practice with time in patients who require blood product transfusion. We analyzed a total 35 (14 Female/21 Male) patients who were diagnosed with MDS from 2002 through 2012 whose data were also available in the blood bank of Gazi University Hospital. We used WHO classification for determination MDS subtype and International Prognostic Scoring System (IPSS) for risk-stratification. The median age was 66.0 (range: 22–88). The most common subtypes were refractory cytopenia with unilineage dysplasia (RCUD) (48.6%), Refractory anemia with excess blasts (RAEB-1) (14.3%) RAEB-2 (14.3%) and chronic myelomonocytic leukemia (CMML-1) (14.3%). The riskstratification for 33 patients was low-risk in30.3%, intermediate-1 in 60.6% and intermediate-2 in9.1%. Among the 25 patients whose molecular studies (FISH) was available, 1 patient had 5q deletion, 1 patient had 7q deletion whereas the others were normal Fifteen patients required treatment and received one of the drugs 5-azacytidine, thalidomide or lenalidomide). Sixty three percent of the patients required transfusion among which 86.4% received packed red blood cells. 45.5% received platelets. Eleven patients were followed a minimum of 24 months. The transfusion requirement of the patients in the first and second 12 month interval were similar. The transfusion requirement was also similar in the first and second year with respect to the MDS subtype, IPSS and treatment status. Median overall survival was 40.5 months (range: 23–79) and median progression free survival was 33.2 months (range 21–65). It might be expected that transfusion requirement to increase with time due to disease progression. Whereas our data show that the transfusion requirement of the patients remained stable in 2 years follow-up. The new generation agents might have delayed the disease progression and increase in transfusion requirement might have been observed with a longer follow up. P-04 ABO MAJOR INCOMPATIBILITY IN ALLOGENEIC BONE MARROW TRANSPLANTATION: RBC REMOVAL WITH COMTEC CELL SEPARATOR P. Accorsi, R. Giancola, C. Passeri, A. Iacone. Dept. of Transfusion Medicine, Pescara Civil Hospital, Dept. of Transfusion Medicine, Pescara Civil Hospital, Italy